- Home
- CECO vs GYRE Comparison
CECO vs GYRE Comparison
Compare CECO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CECO
- GYRE
- Stock Information
- Founded
- CECO 1966
- GYRE 2002
- Country
- CECO United States
- GYRE United States
- Employees
- CECO N/A
- GYRE N/A
- Industry
- CECO Pollution Control Equipment
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CECO Industrials
- GYRE Health Care
- Exchange
- CECO Nasdaq
- GYRE Nasdaq
- Market Cap
- CECO 1.2B
- GYRE 897.1M
- IPO Year
- CECO N/A
- GYRE N/A
- Fundamental
- Price
- CECO $43.53
- GYRE $7.27
- Analyst Decision
- CECO Strong Buy
- GYRE
- Analyst Count
- CECO 5
- GYRE 0
- Target Price
- CECO $42.40
- GYRE N/A
- AVG Volume (30 Days)
- CECO 270.7K
- GYRE 81.2K
- Earning Date
- CECO 07-29-2025
- GYRE 08-12-2025
- Dividend Yield
- CECO N/A
- GYRE N/A
- EPS Growth
- CECO 287.49
- GYRE N/A
- EPS
- CECO 1.43
- GYRE 0.02
- Revenue
- CECO $656,167,000.00
- GYRE $100,643,000.00
- Revenue This Year
- CECO $32.90
- GYRE $21.04
- Revenue Next Year
- CECO $9.01
- GYRE $89.64
- P/E Ratio
- CECO $30.08
- GYRE $92.27
- Revenue Growth
- CECO 15.73
- GYRE N/A
- 52 Week Low
- CECO $17.57
- GYRE $6.11
- 52 Week High
- CECO $43.64
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CECO 89.36
- GYRE 44.07
- Support Level
- CECO $31.00
- GYRE $7.09
- Resistance Level
- CECO $32.44
- GYRE $7.89
- Average True Range (ATR)
- CECO 1.53
- GYRE 0.37
- MACD
- CECO 1.02
- GYRE 0.04
- Stochastic Oscillator
- CECO 98.07
- GYRE 24.39
About CECO CECO Environmental Corp.
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.